Michael N Neely

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission
    Michael Neely
    Division of Pediatric Infectious Diseases, Rainbow Babies and Childrens Hospital, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Afr Health Sci 3:61-7. 2003
  2. ncbi Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers
    Michael Neely
    Maternal Child Adolescent Program, University of Southern California, 1640 Marengo Street, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 54:4619-25. 2010
  3. ncbi Voriconazole pharmacokinetics and pharmacodynamics in children
    Michael Neely
    Division of Pediatric Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Clin Infect Dis 50:27-36. 2010
  4. ncbi Pharmacokinetic optimization of antiretroviral therapy in children and adolescents
    Michael N Neely
    Division of Pediatric Infectious Diseases and Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 50:143-89. 2011
  5. ncbi Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy
    Michael N Neely
    Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Acquir Immune Defic Syndr 44:38-42. 2007
  6. ncbi Management of antiretroviral therapy in neonates, children, and adolescents
    Michael Neely
    Division of Pediatric Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90041, USA
    Curr HIV/AIDS Rep 1:97-104. 2004
  7. ncbi Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization
    Michael Neely
    Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Los Angeles, USA
    J Clin Pharmacol 48:1081-91. 2008
  8. ncbi Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old
    Myron J Levin
    Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, USA
    J Acquir Immune Defic Syndr 55:197-204. 2010
  9. ncbi Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era
    Sharon A Nachman
    Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 163:164-71. 2009
  10. ncbi Pharmacokinetics and safety of caspofungin in older infants and toddlers
    Michael Neely
    Children s Hospital, Los Angeles, California, USA
    Antimicrob Agents Chemother 53:1450-6. 2009

Research Grants

  1. Plasma and Genital HIV Dynamics in Women
    Michael Neely; Fiscal Year: 2007

Detail Information

Publications10

  1. ncbi Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission
    Michael Neely
    Division of Pediatric Infectious Diseases, Rainbow Babies and Childrens Hospital, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Afr Health Sci 3:61-7. 2003
    ..Chloroquine, a cheap, widely available drug, has anti-HIV properties. We conducted a pilot study to determine if chloroquine can reduce HIV vertical transmission...
  2. ncbi Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers
    Michael Neely
    Maternal Child Adolescent Program, University of Southern California, 1640 Marengo Street, Los Angeles, CA 90033, USA
    Antimicrob Agents Chemother 54:4619-25. 2010
    ..UGT1A1 promoter variants did not significantly influence this interaction...
  3. ncbi Voriconazole pharmacokinetics and pharmacodynamics in children
    Michael Neely
    Division of Pediatric Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Clin Infect Dis 50:27-36. 2010
    ..Voriconazole pharmacokinetic and pharmacodynamic data are lacking in children...
  4. ncbi Pharmacokinetic optimization of antiretroviral therapy in children and adolescents
    Michael N Neely
    Division of Pediatric Infectious Diseases and Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, California, USA
    Clin Pharmacokinet 50:143-89. 2011
    ..Discussion of the influences of malnutrition and herbal remedies is also included. Finally, consideration is given to future work in this field...
  5. ncbi Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy
    Michael N Neely
    Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Acquir Immune Defic Syndr 44:38-42. 2007
    ..Among women with low or undetectable quantities of HIV-1 RNA in plasma, factors associated with genital HIV-1 RNA shedding, including choice of treatment regimen, are poorly characterized...
  6. ncbi Management of antiretroviral therapy in neonates, children, and adolescents
    Michael Neely
    Division of Pediatric Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90041, USA
    Curr HIV/AIDS Rep 1:97-104. 2004
    ....
  7. ncbi Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization
    Michael Neely
    Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Los Angeles, USA
    J Clin Pharmacol 48:1081-91. 2008
    ....
  8. ncbi Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old
    Myron J Levin
    Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, USA
    J Acquir Immune Defic Syndr 55:197-204. 2010
    ..Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children...
  9. ncbi Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era
    Sharon A Nachman
    Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 163:164-71. 2009
    ....
  10. ncbi Pharmacokinetics and safety of caspofungin in older infants and toddlers
    Michael Neely
    Children s Hospital, Los Angeles, California, USA
    Antimicrob Agents Chemother 53:1450-6. 2009
    ..Caspofungin at 50 mg/m(2) daily was well tolerated in infants and toddlers; the AUC and caspofungin C(24) were generally comparable to those in adults receiving caspofungin at 50 mg daily...

Research Grants2

  1. Plasma and Genital HIV Dynamics in Women
    Michael Neely; Fiscal Year: 2007
    ..suppression in plasma? 3) Can short-term models of viral dynamics be used to predict long-term responses to therapy? 4) Should women initiate antiretroviral therapy according to different virologic/immunologic criteria than for men? ..